According to a new study, 10-Year survival rates are the same for coronary stenting by drug-eluting stents and bypass surgery in randomized patients having left main coronary artery disease and de novo three-vessel. The results were seen in the “SYNTAX Extended Survival” study that was presented at ESC (European Society of Cardiology) Congress 2019 in cooperation with the World Congress of Cardiology and was published in The Lancet. The subgroup analyses demonstrated that surgery gave a survival benefit for patients having complex coronary artery disease and three-vessel disease, whilst no treatment disparities were seen in patients having left main disease.
Reportedly, ischemic heart disease is a major cause of death worldwide. The CABG (coronary artery bypass grafting) and PCI (percutaneous coronary intervention) are alternatives for patients needing revascularization. The randomized trials correlating PCI through drug-eluting stents and CABG did not show a survival advantage for therapy at mid-term follow-up. The SYNTAX examination is the first large-scale randomized and multicenter study in patients having left main coronary artery and de novo three-vessel disease that underwent PCI by drug-eluting stents or CABG. After a 10-Year follow-up, no survival difference was noted amid PCI by drug-eluting stents and CABG in the largely cohort of patients. Almost, 244 deaths were reported following PCI and 211 following CABG.
On a similar note, recently, a study showed that heart attack and diabetes is a risky combination. Subsequent to a heart attack, patients having diabetes are at a higher peril of heart failure and death compared to those without diabetes. Professor Nicolas Danchin—Principal Investigator of the study from European Hospital Georges Pompidou, France—said, “The findings highlight the significance of avoiding diabetes with better lifestyles, as well as avoiding overweight or obesity by following a healthy diet and doing physical exercise.”